Daiichi Sankyo Co. Ltd., of Tokyo. said the FDA's Cardiovascular and Renal Drugs Advisory Committee voted 9-1 to recommend approval of once-daily Savaysa (edoxaban) 60 mg to reduce the risk of stroke and systemic embolic events (SEE) in patients with nonvalvular atrial fibrillation (NVAF).